Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE Rapporto sulle azioni

Cap. di mercato: US$12.3m

Sensei Biotherapeutics Crescita futura

Future criteri di controllo 0/6

Sensei Biotherapeutics's earnings are forecast to decline at 18.9% per annum. EPS is expected to decline by 1.9% per annum.

Informazioni chiave

-18.9%

Tasso di crescita degli utili

-1.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili27.1%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprio-59.8%
Copertura analitica

Low

Ultimo aggiornamento03 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:SNSE - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026N/A-44N/A-492
12/31/2025N/A-37N/A-402
12/31/2024N/A-31N/A-323
6/30/2024N/A-30-24-24N/A
3/31/2024N/A-32-28-28N/A
12/31/2023N/A-34-32-32N/A
9/30/2023N/A-39-36-35N/A
6/30/2023N/A-45-38-38N/A
3/31/2023N/A-46-40-40N/A
12/31/2022N/A-49-39-39N/A
9/30/2022N/A-46-38-37N/A
6/30/2022N/A-42-37-36N/A
3/31/2022N/A-41-32-30N/A
12/31/2021N/A-37-32-30N/A
9/30/2021N/A-33-27-25N/A
6/30/2021N/A-28-28-25N/A
3/31/2021N/A-23-24-22N/A
12/31/2020N/A-20-19-18N/A
9/30/2020N/A-23-18-17N/A
12/31/2019N/A-21-9-9N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: SNSE is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: SNSE is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: SNSE is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if SNSE's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: SNSE is forecast to have no revenue next year.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: SNSE is forecast to be unprofitable in 3 years.


Scoprire le aziende in crescita